Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0D1ZF
|
|||
| Drug Name |
Mavacamten
|
|||
| Synonyms |
SAR-439152; SAR 439152; SAR439152; MYK-461; MYK 461; MYK461
Click to Show/Hide
|
|||
| Indication | Obstructive hypertrophic cardiomyopathy [ICD-11: BC43.12; ICD-10: I42.1] | Approved | [1] | |
| Company |
Bristol Myers Squibb
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C15H19N3O2
|
|||
| Canonical SMILES |
CC(C)N1C(=O)C=C(NC1=O)NC(C)C2=CC=CC=C2
|
|||
| InChI |
1S/C15H19N3O2/c1-10(2)18-14(19)9-13(17-15(18)20)16-11(3)12-7-5-4-6-8-12/h4-11,16H,1-3H3,(H,17,20)/t11-/m0/s1
|
|||
| InChIKey |
RLCLASQCAPXVLM-NSHDSACASA-N
|
|||
| CAS Number |
CAS 1642288-47-8
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Myosin (MYO) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 214998. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.